Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ether SCHEMBL4725961 | 0.93 | ALDH1A1 (0.33) | ALDH1A1 | |
| Ether SCHEMBL9009598 | 0.93 | ALDH1A1 (0.37) | ALDH1A1 | |
| Ether SCHEMBL28855718 | 0.93 | ALDH1A1 (0.37) | ALDH1A1 | |
| Ether SCHEMBL40006 | 0.93 | — | — | |
| Ether SCHEMBL6535103 | 0.93 | ALDH1A1 (0.37) | ALDH1A1 | |
| Ether SCHEMBL9496506 | 0.90 | ALDH1A1 (0.32) | ALDH1A1 | |
| Ether SCHEMBL23704984 | 0.89 | ALDH1A1 (0.35) | ALDH1A1 | |
| Ether SCHEMBL16446730 | 0.89 | ALDH1A1 (0.35) | ALDH1A1 | |
| Ether SCHEMBL3761236 | 0.86 | ALDH1A1 (0.40) | ALDH1A1 | |
| Ether SCHEMBL10683113 | 0.86 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016035042-A1 | PROCESS FOR THE PREPARATION OF CANAGLIFLOZIN | MYLAN LABORATORIES LTD (IN) | 2016-03-10 | — | — | WO | claimed |
| US-20090227781-A1 | Glycolipid Derivative and Drug Containing the Same as Active Component | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-09-10 | — | — | US | disclosed |
| EP-1905766-A1 | GLYCOLIPID DERIVATIVE AND THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Japan as represented by President of National Center of Neurology and Psychiatry (JP) | 2008-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227781-A1 | Glycolipid Derivative and Drug Containing the Same as Active Component | CD4, UGCG, HRH2 | ALDH1A1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.